CoChat
Sign Up
Cited by 30

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy

Subramanian, Muthiah, Sravani, Vucha, Krishna, Sanga Pavan, Bijjam, Swapnakala, Sunehra, Chandramukhi, Yalagudri, Sachin, Saggu, Daljeet Kaur, Narasimhan, Calambur·2023·The American Journal of Cardiology
DOI 10.1016/j.amjcard.2022.10.054
Open this paper in CoChat — free account

Abstract

The objective of this study was to evaluate the effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on functional capacity and diastolic function in patients with diabetes with nonobstructive hypertrophic cardiomyopathy (nHCM) and preserved left ventricular (LV) function. From January 2019 to October 2020, a prospective open-label study was performed on patients with type 2 diabetes mellitus and nHCM with New York Heart Association class II-III symptoms. Patients with a LV ejection fraction 2 , p = 0.003). There was also an improvement in the 6-minute walk distance (295.1 ± 31.5 vs 343.0 ± 31.1 m, p 2 , p = 0.319) after 6 months of therapy. A patient in the SGLT2i arm discontinued therapy because of a urinary tract infection. In conclusion, the use of SGLT2i improved diastolic function and functional capacity in patients with diabetes with nHCM and a preserved LV function.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2022.10.054

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. Maron, 2016, Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 67, 1399, 10.1016/j.jacc.2016.01.023 · DOI
  2. Maron, 2017, Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored... until now, Am J Med, 130, 119, 10.1016/j.amjmed.2016.09.015 · DOI
  3. Lu, 2018, Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy, J Am Heart Assoc, 7, 10.1161/JAHA.117.006657 · DOI
  4. van der Velden, 2018, Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology, Cardiovasc Res, 114, 1273, 10.1093/cvr/cvy147 · DOI
  5. Olivotto, 2016, Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial, Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.115.002764 · DOI
  6. Olivotto, 2018, Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004124 · DOI
  7. Coats, 2019, Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial, JAMA Cardiol, 4, 230, 10.1001/jamacardio.2018.4847 · DOI
  8. McMurray, 2019, DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303 · DOI · Paper page
  9. Lopaschuk, 2020, Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review, JACC Basic Transl Sci, 5, 632, 10.1016/j.jacbts.2020.02.004 · DOI
  10. Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 16, 233, 10.1093/ehjci/jev014 · DOI
  11. Nagueh, 2016, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 17, 1321, 10.1093/ehjci/jew082 · DOI
  12. Devereux, 1986, Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings, Am J Cardiol, 57, 450, 10.1016/0002-9149(86)90771-X · DOI
  13. Matsutani, 2018, Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes, Cardiovasc Diabetol, 17, 73, 10.1186/s12933-018-0717-9 · DOI
  14. Verma, 2016, Effect of empagliflozin on left ventricular mass and diastolic function in individuals With diabetes: an important clue to the EMPA-REG OUTCOME trial?, Diabetes Care, 39, e212, 10.2337/dc16-1312 · DOI
  15. Shim, 2021, Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDIA trial, Circulation, 143, 510, 10.1161/CIRCULATIONAHA.120.051992 · DOI
  16. Soga, 2018, Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure, Cardiovasc Diabetol, 17, 132, 10.1186/s12933-018-0775-z · DOI
  17. Brown, 2020, A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial, Eur Heart J, 41, 3421, 10.1093/eurheartj/ehaa419 · DOI
  18. Connelly, 2019, Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction, JACC Basic Transl Sci, 4, 27, 10.1016/j.jacbts.2018.11.010 · DOI
  19. Anker, 2020, EMPEROR-Preserved Trial Committees and Investigators. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial, Eur J Heart Fail, 22, 2383, 10.1002/ejhf.2064 · DOI
  20. Scheffer, 2020, Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial, ESC Heart Fail, 7, 4478, 10.1002/ehf2.13055 · DOI
  21. Vakrou, 2014, Hypertrophic cardiomyopathy: a heart in need of an energy bar?, Front Physiol, 5, 309, 10.3389/fphys.2014.00309 · DOI
  22. Verma, 2018, Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors, JACC Basic Transl Sci, 3, 575, 10.1016/j.jacbts.2018.07.006 · DOI

Cited by

Sorted by citations

See all 30

Metadata

Authors
Subramanian, M., Sravani, V., Krishna, S. P., Bijjam, S., Sunehra, C., Yalagudri, S., Saggu, D. K., & Narasimhan, C.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2023-02
Volume
188
Pages
80-86
ISSN
0002-9149
DOI
10.1016/j.amjcard.2022.10.054
Cited by
30
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.amjcard.2022.10.054
The paper
Subramanian, M., Sravani, V., Krishna, S. P., Bijjam, S., Sunehra, C., Yalagudri, S., Saggu, D. K., & Narasimhan, C. (2023). Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2022.10.054